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TMAO is Associated with Mortality: 
Impact of Modestly Impaired Renal 
Function
Eke G. Gruppen1,2, Erwin Garcia3, Margery A. Connelly3, Elias J. Jeyarajah  3, James D. Otvos3, 
Stephan J. L. Bakker1 & Robin P. F. Dullaart2
Trimethylamine-N-Oxide (TMAO) is a microbiome-related metabolite that is cleared by the kidney 
and linked to renal function. We explored the relationship between TMAO and all-cause mortality, 
and determined whether this association was modified by renal function. A prospective study was 
performed among PREVEND participants to examine associations of plasma TMAO with all-cause 
mortality. After median follow-up of 8.3 years in 5,469 participants, 322 subjects died. TMAO 
was positively associated with age, body mass index, type 2 diabetes mellitus and inversely with 
estimated glomerular filtration rate (eGFRcreatcysC)(all P < 0.001). Subjects in the highest versus 
lowest TMAO quartile had a crude 1.86-fold higher mortality risk (Ptrend < 0.001). After adjustment 
for several risk factors, TMAO remained associated with all-cause mortality [HR:1.36 (95% CI, 
0.97–1.91),Ptrend = 0.016]. This association was lost after further adjustment for urinary albumin 
excretion and eGFR [HR:1.15 (95% CI, 0.81–1.64),Ptrend = 0.22]. The association of TMAO with mortality 
was modified by eGFR in crude and age- and sex-adjusted analyses (interaction P = 0.002). When 
participants were stratified by renal function (eGFR < vs. ≥90 mL/min/1.73 m2), TMAO was associated 
with all-cause mortality only in subjects with eGFR <90 mL/min/1.73 m2 [adjusted HR:1.18 (95% 
CI, 1.02–1.36),P = 0.023]. In conclusion, TMAO is associated with all-cause mortality, particularly in 
subjects with eGFR <90 mL/min/1.73 m2.
Trimethylamine-N-Oxide (TMAO) is a metabolite that is produced from trimethylamine containing nutrients, 
such as carnitine, phosphatidylcholine and choline, which are abundant in a Western diet1–14. In animal models, 
TMAO plays a pathogenic role in the development of atherosclerosis2. Clinically, TMAO is increasingly recog-
nized as an important pathophysiological metabolite largely due to its link with adverse cardiovascular (CV) 
outcomes, especially in subjects at high CV risk2–6,8–14. In addition to its association with primary CV events, 
TMAO has been shown to be useful in secondary risk stratification and as a prognostic marker in patients with 
acute coronary syndrome15,16.
TMAO is cleared by the kidney, is linked to impaired renal function and may be related to increased CV risk 
in patients with chronic kidney disease (CKD)17–21. Early interrogation of the potential effects of dietary manip-
ulation in mice, mimicking long-term exposure to elevated TMAO, revealed that TMAO may contribute to pro-
gressive renal fibrosis and renal function impairment18. TMAO levels have been shown to be elevated in subjects 
with advanced CKD17–21. However, equivocal associations of TMAO with renal function and all-cause mortality 
have been reported in subjects with late-stage CKD. Two recent studies demonstrated that serum TMAO pre-
dicted all-cause mortality in CKD patients who were candidates for renal transplantation18,19, while a third study 
reported that TMAO levels were elevated, but not predictive of all-cause mortality in patients new to hemodialy-
sis22. All together, these findings make it relevant to test the extent to which CKD may modify the association of 
TMAO with mortality in the general population.
The aims of this study were i) to explore the relationship between TMAO and all-cause mortality in a large, 
well-characterized population-dwelling cohort and ii) to determine whether this association is modified by renal 
function impairment. To this end we prospectively explored the association of circulating TMAO with mortality 
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in the Prevention of Renal and Vascular End-Stage Disease (PREVEND) study, which focuses on the impact of 
renal function and albuminuria on cardiometabolic disorders.
Materials and Methods
Study design and population. Details of the PREVEND study are described elsewhere23–25, In summary, 
in 1997 through 1998, all inhabitants of the city of Groningen, The Netherlands, between the ages of 28 and 
75 years (85,421 subjects) were asked to send in a morning urine sample and to fill out a short questionnaire. 
Pregnant women and subjects with type 1 diabetes mellitus were excluded. The urinary albumin concentration 
was assessed in 40,856 responders. Subjects with a urinary albumin concentration ≥10 mg/L (n = 7,768) were 
invited to participate, of whom 6,000 were enrolled. In addition, a randomly selected group with a urinary albu-
min concentration of <10 mg/L (n = 3,394) was invited to participate in the cohort, of whom 2,592 were enrolled. 
These 8,592 individuals constitute the initial PREVEND cohort. The second screening took place from 2001 
through 2003 (n = 6,894), which was the starting point of the present evaluation. The PREVEND study has been 
approved by the medical ethics committee of the University Medical Center Groningen, and was performed 
according to the principles outlined in the Declaration of Helsinki. All participants provided written informed 
consent. For the present study, subjects with missing values of TMAO at baseline were excluded, leaving 5,469 
subjects for the analysis (Supplemental Fig. 1).
Follow-up and outcome definitions. Follow-up time was defined as the period between the second screen-
ing round (baseline) and events defined as death, loss to follow-up, or the end of follow up time (01-01-2011), 
whichever came first. If a person had moved to an unknown destination, the date on which the person was dropped 
from the municipal registry was used as the census date. Data on mortality were obtained from the municipal regis-
ter, and the cause of death was obtained by linking the number of the death certificate to the primary cause of death 
as coded by a physician from the Central Bureau of Statistics. All data were coded according to the International 
Classification of Diseases. The Ninth Revision (ICD-9) was used for data until 01-01-2009; after this date, data were 
coded according to the Tenth Revision (ICD-10). CVD was defined as the combined endpoint of incident cardiovas-
cular morbidity and mortality which includes the following events: acute myocardial infarction, acute and subacute 
ischaemic heart disease, occlusion or stenosis of the precerebral or cerebral arteries or the following procedures: 
coronary artery bypass grafting, percutaneous transluminal coronary angioplasty or other vascular interventions 
(i.e. percutaneous transluminal angioplasty or bypass grafting of the aorta and peripheral vessels)26.
Baseline measurements and definitions. Body mass index (BMI) was calculated as weight (kg) divided 
by height squared (meter2). Smoking status was categorized as never, former and current. Blood pressure was 
measured with an automatic Dinamap XL Model 9300 series device (Johnson-Johnson Medical, Tampa, FL, 
USA). Hypertension was defined as a systolic blood pressure (SBP) >140 mmHg or a diastolic blood pressure 
(DPB) >90 mmHg, and/or the use of anti-hypertensive drugs. T2DM was defined as a fasting serum glucose 
level >7.0 mmol/L, a non-fasting plasma glucose level >11.1 mmol/L, self-report of a physician diagnosis and/
or the use of glucose lowering drugs, retrieved from a central pharmacy registry27. Estimated glomerular filtra-
tion rate (eGFRcreat-cysC) was calculated using the combined creatinine cystatin C-based CKD Epidemiology 
Collaboration equation from 201227. eGFRcreat-cysC < and ≥90 mL/min/1.73 m2 was used to stratify subjects 
according to renal function. The urinary albumin concentration was multiplied by urine volume to obtain a value 
in mg per 24 h. The two 24-h urinary albumin values of each subject per examination were averaged.
Laboratory measurements. Subjects were requested to refrain from eating and drinking during 8 hours 
prior to their visit in the outpatient clinic (between 8:00 a. um and 1:00 pm). Blood samples were provided 
and stored at −80 °C. Nuclear magnetic resonance (NMR) spectra were collected from EDTA plasma sam-
ples using the Vantera Clinical Analyzer28. TMAO was quantified from one-dimensional (1D) proton (1H) 
Carr-Purcell-Meiboom-Gill (CPMG) spectra using a deconvolution assay as previously described29. The TMAO 
assay has intra- and inter-assay coefficients of variation (CV%) of 4.3 and 9.8%, respectively, and a limit of quan-
titation of 3.3 µM. Plasma glucose was measured as described30,31. Serum total cholesterol was assayed on an auto-
matic analyzer type MEGA (Merck, Darmstadt, Germany) using the CHOD-PAP-method. Triglycerides (TG) 
and high density lipoprotein cholesterol (HDL-C) were measured on a Beckman Coulter AU Analyzer (Beckman 
Coulter, Brea, CA). LDL-C was calculated using the Friedewald formula in case of triglycerides <4.5 mmol/L. 
Non-HDL-C was calculated as the difference between TC and HDL-C. Measurement of serum creatinine was 
performed by an enzymatic method on a Roche Modular analyzer (Roche Diagnostics, Mannheim, Germany). 
Serum cystatin C concentrations were measured by Gentian Cystatin C Immunoassay (Gentian AS, Moss, 
Norway) on a Modular analyzer (Roche Diagnostics). Urinary albumin excretion (UAE) was measured by neph-
elometry with a threshold of 2.3 mg/L, and intra- and inter-assay CV% of 2.2% and 2.6%, respectively, (Dade 
Behring Diagnostic, Marburg, Germany).
Statistical analysis. Statistical analyses were performed using statistical software SPSS version 22.0 (SPSS Inc, 
Chicago, IL) and STATA version 13.1 (StataCorp, College Station, TX: StataCorp LP). Normally distributed data 
were expressed as mean ± SD and skewed data as median [interquartile range]. Skewed data were normalized by 
logarithmic transformation before analyses, which was the case for triglycerides, UAE and TMAO. TMAO values of 
0.0 µM were replaced with 0.1 µM for statistical analysis purposes. Crude as well as age- and sex- adjusted Pearson 
correlation coefficients were calculated to explore relationships between clinical variables. Cox proportional haz-
ards regression analyses were used to determine the risk for incident all-cause mortality according to quartiles of 
TMAO, as well as per 1 SD increment in TMAO. The assumption of proportional hazards for baseline predictors was 
investigated by inspecting the Schoenfeld residuals. Cox regression analyses with restricted cubic splines with three 
knots were carried out to show the association between TMAO and all-cause mortality. Multivariable analyses were 
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conducted using Cox regression models including the covariates age, sex, BMI, smoking status, prevalent T2DM, 
history of CVD, history of cancer, use of anti-hypertensive medication, use of lipid lowering drugs, SBP, total choles-
terol, HDL-C, triglycerides, eGFR, and UAE. Tests of trend across quartiles were conducted by assigning the median 
value for each quartile as its value and treating this as a continuous variable32. An advantage of this method is that 
is allows for use of all the intra-categorical information that is otherwise ignored by mere categorical comparisons. 
Possible effect modification was explored by including interaction terms between TMAO and age, sex, eGFR and 
HDL-C, in crude as well as in age- and sex-adjusted models. We carried out a mediation analysis to discern whether 
eGFR was a possible mediator between all-cause mortality and circulating TMAO levels following procedures out-
lined by Preacher and Hayes33,34. Covariates included age and sex. The bootstrapping technique advocated in this 
method was also employed. Cox proportional hazard regression analysis was also used to determine the risk for 
CVD. Interaction terms were considered to be statistically significant at two-sided P-values < 0.1035. Otherwise, the 
level of significance was set at two-sided P-values < 0.05. Given the enrichment of subjects with elevated UAE in 
PREVEND population, we also performed a secondary analysis in which we accounted for the sampling design of 
the study by using stratum-specific baseline hazard functions.
Results
The clinical and laboratory characteristics of the 5,469 subjects are summarized in Table 1. The mean age of the 
study population was 53.5 ± 12.0 and the median TMAO level was 3.2 µM [1.71–5.70]. A history of CVD and 
T2DM were more prevalent among subjects in the highest quartile of TMAO. Levels of eGFR were lower in 
subjects in the highest quartile vs. subjects in the lowest TMAO quartile, whereas UAE >30 mg/24 h were more 
prevalent in subjects in the highest TMAO quartile.
Pearson correlation coefficients between various clinical and laboratory variables and TMAO are given in 
Table 2. Univariable correlation analyses showed that age, BMI, hypertension, history of CVD, T2DM, SBP, tri-
glycerides and UAE were positively associated with TMAO, whereas the female sex, current smoking, HDL-C 
and eGFR were inversely associated with TMAO. After adjustment for age and sex, TMAO was still positively 
correlated with age, BMI, T2DM and UAE, and inversely with current smoking, HDL cholesterol and eGFR.
After a median follow-up period of 8.3 (7.8–8.8) years 322 (6.3%) subjects died. In unadjusted Cox regres-
sion models, higher plasma TMAO (the highest quartile) was associated with a 86% increased risk for all-cause 
mortality compared to the lowest quartile of TMAO (Table 3). Kaplan Meier curves are shown in Figs 1 and 
2 shows an age- and sex- adjusted cubic spline for the association of TMAO with all-cause mortality. TMAO 
was independently associated with all-cause mortality in models adjusted for age, sex, BMI, smoking, T2DM, 
history of CVD, history of cancer, anti-hypertensive medications, lipid lowering drugs, SBP, total cholesterol, 
HDL-C and triglycerides (P for trend = 0.016, Table 3; model 1–3). The P-value for trend remained significant 
after adjustment for UAE (P = 0.049, model 4a). However, significance was lost after further adjustment for eGFR 
(P for trend = 0.15, model 4b). Comparable results were found in analysis with TMAO as a continuous variable, 
although statistical significance was lost after adjustment for UAE (model 4a). Furthermore, in crude, as well as in 
age- and sex-adjusted models and in models additionally adjusted for UAE, eGFR was associated with all-cause 
mortality (HR: 0.86, 95% CI: 0.75–0.98, P = 0.026 in age-, sex- and UAE-adjusted models).
The interaction terms between TMAO and age, sex, HDL-C and UAE were not significantly associated with 
all-cause mortality when included in the crude model (P for interaction >0.10 for all). Notably, however, the 
interaction term between TMAO and eGFR was significantly associated with all-cause mortality when included 
in crude and in the age- and sex-adjusted analyses (P for interaction 0.003 and 0.002, respectively).
Table 4 shows the Cox proportional hazards analysis stratified by eGFR (eGFRcrea-cysC ≥90 and <90 mL/
min per 1.73 m2). Median TMAO levels were higher in the group with impaired renal function compared to 
the group with normal renal function (Table 4, P < 0.001). In the group with eGFRcrea-cysC ≥90 mL/min per 
1.73 m2, TMAO was not significantly associated with all-cause mortality. Notably, in the group with eGFR <90, 
TMAO was significantly associated with all-cause mortality in crude analysis, as well as in models adjusted for 
age- and sex, and additionally for UAE.
In a secondary analysis, in which we accounted for the design of the PREVEND study with preferential inclu-
sion of subjects with elevated UAE results remained essentially the same. The association between TMAO and 
all-cause mortality remained significant after adjustment for clinical covariates. Again, significance was lost when 
eGFR was included in the model (Supplemental Table 1).
A mediation model is shown in Fig. 3. eGFR appeared to be a mediator in the association of TMAO with 
all-cause mortality. The indirect pathway was significant (β = 0.008, 95% CI: 0.002–0.016, P-indirect <0.005). 
The magnitude of mediation was 15% (Table 5).
Supplemental Table 2 shows the results for TMAO and CVD. During follow-up 525 CVD events occurred. 
Because of the non-linear association between TMAO and CVD, results are presented with quartiles of TMAO. In 
crude as well as in and age- and sex- adjusted analysis TMAO in the highest quartile (≥5.7 µM) was significantly 
associated with CVD risk (P for trend <0.001 and 0.033). However, after multivariable adjustment, the P for trend 
was no longer significant (model 3).
Discussion
This prospective study of 5,469 PREVEND study participants demonstrates that the microbiome-related metab-
olite, TMAO, is associated with all-cause mortality. Remarkably, the association of TMAO with mortality was 
attenuated after adjustment for albuminuria and became insignificant after adjustment for eGFR. In line, in sub-
jects with any degree of decreased eGFR, TMAO was significantly associated with all-cause mortality even when 
taking account of albuminuria. In contrast, in subjects with normal renal function TMAO was not associated with 
mortality. Thus, a novel finding of our study is that the association of TMAO with mortality is modified by renal 
function in such a way that the association of TMAO with mortality is stronger in subjects with a lower eGFR.
www.nature.com/scientificreports/
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While NMR was used in our study, other methods such as liquid chromatography tandem mass spec-
trometry (LC/MS-MS) are also available to quantify circulation TMAO levels36–39. Most of the clinical studies 
published using LC/MS-MS assays to date were conducted in populations of subjects at high CV risk with 
median TMAO levels ranging from 3.7–5.0 µM4,6,10,16,40. We sought to understand TMAO-disease associations 
in a population of subjects who were generally not at high CV risk, and whose median [interquartile range 
(IQR)] TMAO level was lower (3.2 [1.7–5.7] µM) than the previous studies. We did not observe an independ-
ent association between TMAO and CV outcomes in this population after adjustment for relevant covariates. 
This result appears to be in concert with other reports showing that TMAO may particularly predict (recur-
rent) CV events in high CV risk populations2–6,8–14. Of further interest, TMAO was lower in women but this 
difference was lost after controlling for age. In addition, TMAO was lower in subjects who were classified as 
current smokers at entry in the study. Lower TMAO levels in women could be attributable to sex differences in 
dietary habits such as lower intake of animal protein and lower egg consumption in women41. The association 
of TMAO with smoking may be explained by effects of smoking on intestinal microbiotica42, although this 
clearly needs further evaluation.
Early interrogation of the potential effects of diets, mimicking long-term exposure to elevated TMAO, in 
mice revealed that TMAO may directly contribute to progressive renal fibrosis and dysfunction18. Nonetheless, 
Quartiles of TMAO, µM
Q1 < 1.70 Q2 ≥ 1.71 Q3 ≥ 3.17 Q4 ≥ 5.70 P-value
Participants, n 1361 1373 1367 1368
Age 48.7 ± 11.4 53.7 ± 11.7 55.5 ± 12.2 54.1 ± 12.0 <0.001
Sex, n (%) <0.001
 M 624 (45.8) 712 (51.9) 718 (52.5) 607 (44.4)
 F 737 (54.1) 661 (48.1) 649 (47.5) 761 (55.6)
BMI, kg/m2 26.1 ± 4.3 26.5 ± 4.2 27.0 ± 4.4 27.1 ± 4.6 <0.001
Smoking status, n (%) 0.03
 Non smoker 919 (67.5) 999 (73.0) 986 (72.1) 982 (71.8)
 Current smoker 415 (30.5) 359 (26.3) 363 (26.6) 374 (27.3)
Hypertension, n (%) 374 (27.5) 450 (32.9) 516 (37.7) 471 (34.4) 0.003
Lipid lowering drug use, n (%) 106 (7.8) 119 (8.7) 156 (11.4) 142 (10.3) 0.005
History of CVD, n (%) 61 (4.5) 81 (5.9) 105 (7.7) 96 (7.0) 0.003
History of cancer, n (%) 67 (4.9) 81 (5.9) 75 (5.5) 89 (6.5) 0.33
T2DM, n (%) 53 (3.9) 67 (4.9) 96 (7.0) 120 (8.8) <0.001
Blood pressure lowering drug use, n (%) 237 (17.4) 268 (19.5) 343 (25.1) 321 (23.5) <0.001
Glucose lowering drug use, n (%) 30 (2.2) 40 (2.9) 57 (4.2) 72 (5.3) <0.001
SBP, mmHg 123.5 ± 18.1 126.5 ± 18.7 128.0 ± 18.4 125.9 ± 19.8 <0.001
Total cholesterol, mmol/L 5.3 ± 1.0 5.5 ± 1.0 5.5 ± 1.1 5.4 ± 1.0 <0.001
Non-HDL cholesterol, mmol/L 4.1 ± 1.0 4.2 ± 1.0 4.2 ± 1.0 4.1 ± 1.0 <0.001
LDL cholesterol, mmol/L 1.29 ± 0.41 1.32 ± 0.41 1.31 ± 0.43 1.27 ± 0.41 0.005
HDL cholesterol, mmol/L 1.3 ± 0.3 1.3 ± 0.3 1.2 ± 0.3 1.2 ± 0.3 0.02





eGFRcrea-cysC, mL/min/1.73 m2 96.7 ± 14.8 92.8 ± 15.9 90.2 ± 17.0 89.6 ± 19.5 <0.001
eGFRcrea-cysC, mL/min/1.73 m2, categorical <0.001
≥90 953 (70.0) 839 (61.3) 777 (56.8) 767 (56.1)
≥60 392 (28.8) 504 (36.9) 524 (38.3) 499 (36.5)
≥30 16 (1.2) 30 (2.2) 64 (4.7) 92 (6.7)
<30 0 (0) 0 (0) 2 (0.1) 10 (0.7)
UAE, mg/24 h 8.5 [5.9–14.0] 8.4 [6.0–37.9] 9.2 [6.3–17.4] 8.8 [6.0–18.1] <0.001
UAE, mg/24 h, categorical <0.001
>30 145 (10.7) 161 (11.8) 195 (14.3) 234 (17.2)
≤30 1206 (89.3) 1207 (88.2) 1167 (85.7) 1126 (82.8)
Table 1. Baseline characteristics of the 5,469 subjects of the Prevention of Renal and Vascular End-Stage Disease 
(PREVEND) study according to quartiles of TMAO, µM. Data are numbers (percentages), means (SD) or 
medians [interquartile range (IQR)]. P-values were calculated by linear regression analysis or χ2 analysis. P-values 
were based on analysis of variance (nonskewed continuous variables), Kruskal–Wallis test (skewed continuous 
variables), or χ2 (categorical variables). Triglycerides, UAE and TMAO were logarithmically transformed for 
analysis. LDL was calculated in 5,372 subjects with fasting triglycerides <4.5 mmol/L. Abbreviations: BMI, body 
mass index; CVD, cardiovascular disease; eGFRcrea-cysC, estimated glomerular filtration rate based on creatinine-
cystatin C equation; LDL, low density lipoprotein; HDL, high density lipoprotein; SBP, systolic blood pressure; 
TMAO, trimethylamine N-oxide; T2DM, type 2 diabetes mellitus; UAE, urinary albumin excretion.
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studies of the associations of TMAO with renal function and all-cause mortality in subjects with late-stage 
CKD have been mixed. One recent study reported that circulating TMAO predicted all-cause mortality in 
CKD patients who were candidates for renal transplantation19, while a second study reported that TMAO levels 
were elevated, but were not associated with all-cause mortality in patients new to dialysis22. Our study furthers 
this research by showing that TMAO is associated with all-cause mortality in subjects with any degree of renal 
function impairment, but not in subjects with normal renal function. Whether or not TMAO is a causative 
factor in the progression of renal or CV disease in humans deserves further study. However, it is clear from the 
current literature that TMAO is a prognostic marker, especially in subjects with CKD, independent of other 
CVD risk factors.
TMAO, µM Age- and sex-adjusted
Clinical parameter Pearson correlation P-value Pearson correlation P-value
Age 0.125 <0.001 0.1251 <0.001
Sex
 M Reference Reference
 F −0.027 0.046 −0.0162 0.242
BMI, kg/m2 0.09 <0.001 0.068 <0.001
Smoking status
 Non smoker Reference Reference
 Current smoker −0.040 0.003 −0.030 0.032
 Hypertension 0.061 <0.001 0.007 0.668
 History of CVD 0.044 0.001 0.025 0.115
 T2DM 0.082 <0.001 0.075 <0.001
 SBP, mmHG 0.059 <0.001 0.008 0.597
 Total cholesterol, mmol/L 0.013 0.343 −0.022 0.159
 HDL cholesterol, mmol/L −0.044 0.001 −0.041 0.009
 Triglycerides, mmol/L 0.044 0.001 0.022 0.158
 eGFRcrea-cysC (mL/min per 1.73 m2) −0.160 <0.001 −0.095 <0.001
UAE, mg/24 h 0.084 <0.001 0.062 <0.001
Table 2. Pearson correlation coefficient between various clinical and laboratory variables and trimethylamine 
N-oxide (TMAO) (n = 5,469). Triglycerides, UAE and TMAO were logarithmically transformed for correlation 
analysis. 1Adjusted for sex. 2Adjusted for age. Abbreviations: BMI, body mass index; CVD, cardiovascular 
disease; eGFRcrea-cysC, estimated glomerular filtration rate based on creatinine-cystatin C equation; HDL, 
high density lipoproteins; SBP, systolic blood pressure; TMAO, trimethylamine N-oxide; T2DM, type 2 diabetes 
mellitus; UAE, urinary albumin excretion. Statistically significant correlations are shown in bold print.
Q1 Q2 P-value Q 3 P-value Q 4 P-value
P-value 
for trend
TMAO per 1 SD 
increment P-Value
Subjects, n 1361 1373 1367 1368
TMAO range, µM <1.71 ≥1.71–3.17 ≥3.17–5.70 ≥5.70
No. of deaths 55 68 95 104
Crude (ref) 1.22 [0.86–1.75] 0.27 1.71 [1.23–2.38] 0.002 1.86 [1.34–2.58] <0.001 <0.001 1.28 [1.15–1.43] <0.001
Model 1 (ref) 0.98 [0.69–1.40] 0.90 1.05 [0.75–1.47] 0.76 1.37 [0.99–1.90] 0.06 0.01 1.13 [1.01–1.27] 0.03
Model 2 (ref) 1.00 [0.70–1.44] 0.99 1.11 [0.80–1.56] 0.53 1.41 [1.01–1.96] 0.04 0.009 1.15 [1.03–1.29] 0.016
Model 3 (ref) 0.96 [0.67–1.39] 0.85 1.06 [0.75–1.50] 0.72 1.36 [0.97–1.91] 0.07 0.016 1.14 [1.01–1.28] 0.028
Model 4a (ref) 0.95 [0.66–1.38] 0.80 1.03 [0.73–1.46] 0.86 1.28 [0.91–1.80] 0.15 0.049 1.11 [0.99–1.25] 0.07
Model 4b (ref) 0.93 [0.64–1.35] 0.71 1.00 [0.70–1.42] 0.98 1.20 [0.84–1.71] 0.32 0.15 1.08 [0.95–1.22] 0.23
Model 4c (ref) 0.92 [0.64–1.34] 0.68 0.97 [0.68–1.38] 0.87 1.15 [0.81–1.64] 0.44 0.22 1.06 [0.94–1.20] 0.34
Table 3. Association between trimethylamine N-oxide (TMAO) and all-cause mortality in 5,469 (322 cases) 
subjects of the Prevention of Renal and Vascular End-Stage Disease (PREVEND) study according to quartiles 
(Q1-Q4) and as continuous variable. Hazard ratios and 95% confidence intervals were derived from Cox 
proportional hazards regression models. TMAO was logarithmically transformed before analysis. 1 SD change 
in TMAO corresponds to 2.94 µM (antilog). Model 1: age and sex. Model 2: Model 1 + body mass index and 
smoking. Model 3: Model 2 + type 2 diabetes mellitus, history of cardiovascular disease, history of cancer, 
anti-hypertensive medication, lipid lowering drugs, systolic blood pressure, total cholesterol, high density 
lipoprotein cholesterol and triglycerides. Model 4a: Model 3 + urinary albumin excretion (UAE). Model 4b: 
Model 3 + eGFR crea-cysC (estimated glomerular filtration rate based on creatinine-cystatin C equation). 
Model 4c: Model 3 + UAE and eGFR crea-cysC. Statistically significant correlations are shown in bold print.
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Recent reports have shown that circulating levels of TMAO are elevated in several chronic diseases such 
as obesity43, non-alcoholic fatty liver disease44,45, T2DM12 and heart failure40,46, thus raising the possibility 
that this microbiome-related metabolite could contribute to the increased CV risk in these often coexisting 
conditions. Of particular relevance, metabolites like TMAO are cleared by the kidney, and are therefore 
often linked to impaired renal function17–19. Elevated TMAO levels in subjects with an impaired renal func-
tion may be explained by higher production, reduced clearance or both17. Our study extends these earlier 
results by showing an inverse relationship of TMAO with eGFR in a large, well defined population-based 
cohort22–24. However, the potential mechanisms by which higher TMAO levels predict increased mortality 
risk, particularly in subjects with (mild to severe) renal function impairment remain incompletely under-
stood. In an exploratory mediation analysis, set up to discern whether renal function makes part of the 
causal pathway of TMAO with mortality risk it was found that eGFR in part explained the association of 
TMAO with mortality. On the other hand, TMAO may directly contribute to progressive renal fibrosis and 
dysfunction in mice18, although equivocal associations of TMAO with renal function and all-cause mortal-
ity have been documented in humans with late-stage CKD18,19. Thus it is also possible that TMAO could 
contribute to renal function impairment which in turn is a determinant of mortality. Therefore, there may 
be a mutual cause and effect relationship between increased TMAO and chronic kidney disease adversely 
impacting on mortality23,39.
Several other methodological aspects of our study should be addressed. We consider the comprehensive 
assessment of laboratory variables, including lipoprotein fractions, eGFR and albuminuria in a large pop-
ulation of men and women a strength of our study. Notably, the PREVEND study population consists pre-
dominantly of Caucasians. Therefore, the applicability of the current results to other ethnic groups remains 
uncertain. Furthermore, as done in the present report, most epidemiological studies use a single baseline 
Figure 1. Kaplan-Meier curves of all-cause mortality according to quartiles of trimethylamine N-oxide 
(TMAO), P ≤ 0.001by log-rank test.
Figure 2. Association between trimethylamine N-oxide (TMAO) and all-cause mortality. Data were fit by a 
Cox proportional hazards regression model that was based on restricted cubic splines and adjusted for age and 
sex. The reference standard was mean TMAO level of 2.92 µM (antilog). The gray areas represent 95% CIs.
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measurement for studying the association of variables with outcomes. Given the variability of TMAO over 
time47, this is anticipated to result in underestimation of the true strength of the association of this variable 
with outcome48,49. Further, the PREVEND cohort is enriched with subjects with elevated albuminuria. In the 
present report, the association of TMAO with outcome was only modestly modified by albuminuria, which 
itself is a determinant of worse outcome50. Moreover, in a secondary analysis, taking account of albuminuria 
enrichment in the cohort, a similar association of TMAO with mortality was observed which was again lost 
eGFRcrea-cysC ≥90 mL/min per 1.73 m2)
Subjects (deaths) 3336 (103) P-value
TMAO (µM) 2.91 [1.54–5.43]
eGFRcreatcysC (mL/min per 
1.73 m2) 103.7 ± 9.0
Crude 1.08 [0.91–1.30] 0.38
Model 1 0.99 [0.82–1.21] 0.97
Model 2 0.97 [0.80–1.18] 0.77
eGFRcrea-cysC <90 mL/min per 1.73 m2)
Subjects (deaths) 2133 (219) P-value
TMAO (µM) 3.66 [2.04–6.11]
eGFRcreatcysC (mL/min per 
1.73 m2) 76.0 ± 12.1
Crude 1.29 [1.12–1.48] <0.001
Model 1 1.21 [1.05–1.39] 0.009
Model 2 1.18 [1.02–1.36] 0.023
Table 4. Association of trimethylamine N-oxide (TMAO) with all-cause mortality stratified by renal function 
(eGFRcrea-cysC) in 5,469 (322 cases) subjects of the Prevention of Renal and Vascular End-Stage Disease 
(PREVEND) study. Median [IQR] TMAO levels are given. Hazard ratios and 95% confidence intervals were derived 
from Cox proportional hazards regression models. TMAO was logarithmically transformed before analysis. 1 SD 
change in TMAO corresponds to 2.94 µM (antilog). Model 1: age, sex. Model 2: Model 1 + UAE. Abbreviations: eGFR 
crea-cysC, estimated glomerular filtration rate based on creatinine-cystatin C equation; TMAO, trimethylamine 
N-oxide; UAE, urinary albumin excretion. Statistically significant correlations are shown in bold print.
Figure 3. Mediation analysis on the association of TMAO with all-cause mortality. A, b and c are the standard 
regression coefficients between variables. The indirect effect is calculated as a * b. Total effect (c) is a * b + c’. 
Magnitude of mediation is calculated as indirect effect divided by total effect.
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after further adjustment for eGFR. Finally, no information about dietary habits that could affect TMAO con-
centrations was available.
In conclusion, this prospective cohort study demonstrates that TMAO, a marker of the microbiome, is asso-
ciated with all-cause mortality, independent of clinical and laboratory variables particularly in subjects with mild 
to severe renal function impairment.
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